SCHEMBL2666367

SCHEMBL2666367

Cc1ccnc(-n2ccnc2C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
CYP2E1 P05181 1/20 0.44
CYP2A6 P11509 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KDR P35968 1/20 0.41
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40
TUBB2A Q13885 2/20 0.40
TUBB8 Q3ZCM7 2/20 0.40
TUBA3E Q6PEY2 2/20 0.40
TUBA1A Q71U36 2/20 0.40
TUBA1C Q9BQE3 2/20 0.40
TUBB6 Q9BUF5 2/20 0.40
TUBB2B Q9BVA1 2/20 0.40
TUBB1 Q9H4B7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12918510 0.80 CYP3A4 (0.43) CYP3A4CYP2E1CYP2A6ALDH1A1KDR
SCHEMBL9026494 0.79 CYP3A4 (0.48) CYP3A4CYP2E1CYP2A6ALDH1A1KDR
SCHEMBL15331102 0.78 CYP3A4 (0.39) CYP3A4CYP2E1CYP2A6ALDH1A1KDR
SCHEMBL15984839 0.71 HCRTR1 (0.44) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL27961165 0.71 TSHR (0.49) CYP3A4CYP2E1CYP2A6ALDH1A1KDR
SCHEMBL2666269 0.70 CYP3A4 (0.42) CYP3A4ALDH1A1CYP2D6CYP2C9KDM4E
SCHEMBL30558759 0.70 ALDH1A1 (0.71) CYP3A4CYP2E1CYP2A6ALDH1A1CYP1A2
SCHEMBL1878679 0.69 KDM4E (0.53) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL28728263 0.69 CYP3A4 (0.48) CYP3A4CYP2E1CYP2A6ALDH1A1KDR
SCHEMBL18161055 0.68 KDM4E (0.45) ALDH1A1CYP2C9KDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940771-B2 Organic compounds NOVARTIS AG (CH) 2015-01-27 US disclosed
US-8940771-B2 Organic compounds NOVARTIS AG (CH) 2015-01-27 US disclosed
US-20090163469-A1 Organic Compounds NOVARTIS AG 2009-06-25 US disclosed
US-20090163469-A1 Organic Compounds NOVARTIS AG 2009-06-25 US disclosed
WO-2002076983-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163469-A1 Organic Compounds PIK3C3, PIK3CA, PIK3CD CYP3A4 806/4885CYP2E1 1135/4885CYP2A6 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.